Neurocrine Biosciences (NBIX) EV to EBITDA (2011 - 2026)
Neurocrine Biosciences' EV to EBITDA was 19.87 in Q2 2026, down 9.3% from 21.91 a year earlier but up 36.3% from the prior quarter.
Powered by 
Analysis
Neurocrine Biosciences (NBIX) EV to EBITDA (2011 - 2026) Analysis & Trends
On a trailing twelve-month basis, Neurocrine Biosciences' EV to EBITDA was 15.23 through Jun 30, 2026, down 3.0% year-over-year; for FY2025, it came in at 19.59, down 6.3% from FY2024.
- In earlier years, EV to EBITDA was 20.90 in FY2024 (-52.4%), 43.96 in FY2023 (+10.5%), 39.79 in FY2022 (-38.8%) and 64.97 in FY2021 (+36.7%).
- Quarterly EV to EBITDA has moved between 14.58 (Q1 2026) and 109.76 (Q2 2022) over five years.
- Compared with a year earlier, EV to EBITDA has declined for three straight quarters, with an average decline of 19.4% over the last eight quarters.
- The best year-over-year quarter for EV to EBITDA over five years was Q3 2022 (growth of 101.9%); the worst was Q3 2024 (a decline of 61.2%).
- Per Business Quant data, NBIX's EV to EBITDA in the three quarters before Q2 2026 was 14.58 (Q1 2026), 19.59 (Q4 2025) and 22.21 (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.01 Bn | 563.54 Bn | 17.26 Bn |
| 2 | AbbVie | 465.23 Bn | 438.39 Bn | 12.70 Bn |
| 3 | Merck | 368.40 Bn | 322.83 Bn | 12.21 Bn |
| 4 | Novartis Ag | 278.02 Bn | 233.89 Bn | 11.24 Bn |
| 5 | Astrazeneca | 254.57 Bn | 228.13 Bn | 12.86 Bn |
| 6 | Amgen | 229.02 Bn | 184.42 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 187.74 Bn | 161.85 Bn | 6.22 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn |
| 9 | Vertex Pharmaceuticals | 133.45 Bn | 105.45 Bn | 2.84 Bn |
| 10 | Neurocrine Biosciences | 14.06 Bn | 9.76 Bn | 935.80 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 19.87 |
| Mar 31, 2026 | 14.58 |
| Dec 31, 2025 | 19.59 |
| Sep 30, 2025 | 22.21 |
| Jun 30, 2025 | 21.91 |
| Mar 31, 2025 | 19.12 |
| Dec 31, 2024 | 20.90 |
| Sep 30, 2024 | 17.26 |
| Jun 30, 2024 | 22.91 |
| Mar 31, 2024 | 26.01 |
| Dec 31, 2023 | 43.96 |
| Sep 30, 2023 | 44.43 |
| Jun 30, 2023 | 48.65 |
| Mar 31, 2023 | 60.23 |
| Dec 31, 2022 | 39.79 |
| Sep 30, 2022 | 76.17 |
| Jun 30, 2022 | 109.76 |
| Mar 31, 2022 | 96.60 |
| Dec 31, 2021 | 64.97 |
| Sep 30, 2021 | 37.73 |
API Access
Neurocrine Biosciences EV to EBITDA API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ev-to-ebitda&ticker=NBIX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ev-to-ebitda", "ticker": "NBIX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ev-to-ebitda&ticker=NBIX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();